Because the expression of HER2 is generally high in patients with SDC and adenocarcinoma NOS [59], anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel showed excellent ORR ranging from 60–72% in patients with SDC [96,97,98]. Here, ERBB2 is linked to adenocarcinoma.